Trinity Biotech plc announced on February 28, 2025, that it has obtained an additional $4 million in debt financing from its primary lender, Perceptive Advisors. This additional liquidity is intended to support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring (CGM) technology and the company’s comprehensive transformation plan. The company continues to focus much of its growth efforts around its CGM technology, especially given previously announced positive results from its most recent pre-pivotal trial.
The company's comprehensive transformation plan is focused on increasing profitability and cash-flow generation across its portfolio of operating businesses. Since the announcement of the transformation plan, Trinity Biotech has taken steps to increase operational efficiencies with a view to increasing its financial strength. The company will continue to review and manage the optimization of its business portfolio and capital structure.
This financing underscores the ongoing commitment to strengthening the company's financial foundation. The additional funds will help advance critical initiatives and further position Trinity Biotech for future growth and profitability. This move follows previous amendments to credit agreements with Perceptive Advisors, demonstrating a continued partnership.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.